Jan 14, 2025 · The FTC’s second interim staff report analyzed all specialty generic drugs dispensed from 2017 to 2022 for members of commercial health plans and Medicare Part D prescription drug plans managed by the Big 3 PBMs for which the FTC has relevant data.

The interim staff report, which is part of an ongoing inquiry launched in 2022 by the FTC, details how increasing vertical integration and concentration has enabled the six largest PBMs to manage nearly 95 percent of all prescriptions filled in the United States.

This Interim Report is part of an ongoing study by the Federal Trade Commission (“FTC” or the “Commission”) of pharmacy benefit managers (“PBMs”) and their impact on access to and affordability of medicines.

6 days ago · PBM Policy and Legislative Update – Special Edition: FTC Interim Report Mintz | 2 Second Report Key Findings • Markups for Specialty Generic Drugs Dispensed at PBM-Affiliated Pharmacies.

Jan 22, 2025 · At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report (Second Report) stemming from its investigation into pharmacy benefit managers (PBMs) and their impacts on competition in the health care marketplace. The Second Report, released following a unanimous vote of the commissioners, expands on aContinue Reading

Jul 12, 2024 · In this Special Edition of the PBM Policy and Legislative Update, we paired up with our Antitrust colleagues to highlight the FTC’s recent activity in investigating the potential competitive consequences from conduct in the PBM industry, including Commissioner Melissa Holyoak’s dissenting statement regarding the Interim Report, and reports of a ...

Jul 11, 2024 · An interim report released July 9 by the FTC highlights the “enormous power” third party players, known as pharmacy benefit managers (PBMs), have over prescription drug access and affordability in the U.S.

Jul 9, 2024 · Pharmacy benefit managers, which negotiate the terms for prescription drug access for hundreds of millions of Americans, are racking up profits while squeezing patients and independent...

Jan 24, 2025 · Last year, the Federal Trade Commission (FTC) caused consternation among pharmacy benefit managers (PBMs) after it claimed the middlemen in the pharma supply chain were ramping up costs for...

Jul 11, 2024 · The FTC blasted pharmacy benefit managers, accusing them of raising patients’ costs and driving pharmacies out of business. The FTC is planning to sue the 3 largest PBMs.